A Gut-Centric Model of Metabolic Homeostasis

Harith Rajagopalan, MD, PhD1, Juan Carlos Lopez-Talavera, MD, PhD1, David C. Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE2, and Alan D. Cherrington, PhD3

Abstract
Modern changes in diet and lifestyle have led to an explosion of insulin resistance and metabolic diseases around the globe which, if left unchecked, will become a principal driver of morbidity and mortality in the 21st century. The nature of the metabolic homeostatic shift within the body has therefore become a topic of considerable interest. While the gut has long been recognized as an acute nutrient sensor with signaling mechanisms to the other metabolic organs of the body, its role in regulating the body’s metabolic status over longer periods of time has been underappreciated. Recent insights from bariatric surgery and intestinal nutrient stimulation experiments provide a window into the adaptive role of the intestinal mucosa in a foregut/hindgut metabolic balance model that helps to define metabolic parameters within the body—including the metabolic regulation of insulin resistance versus sensitivity, hunger versus satiety, energy utilization versus energy storage, and protection from hypoglycemia versus protection from hyperglycemia. This intestinal metabolic balance model provides an intellectual framework with which to understand the distinct roles of proximal and distal intestinal segments in metabolic regulation. The model may also aid in the development of novel disease-modifying therapies that can correct the dysregulated metabolic signals from the intestine and stem the tide of metabolic diseases in society.

Keywords
bariatric surgery, duodenal mucosal resurfacing, duodenum, insulin resistance, type 2 diabetes

Introduction
The Type 2 Diabetes (T2D) epidemic is global and growing. Despite broad availability and access to lifestyle therapies and multiple classes of anti-diabetic medications, the vast majority of patients with T2D still do not achieve optimized glycemic control or risk factor reduction. In fact, fewer than one third of patients with T2D achieve and maintain the generally accepted HbA1c goal of 7% or less for adult T2D patients.1 A marked discrepancy has emerged between increasingly impressive results from controlled clinical trials of new drugs and stagnant real-world outcomes in disease treatment. This difference is principally due to fundamental gaps in real world outcomes that current drug therapies have not been able to fill: excessive dependence on adherence,2 lack of durable disease modification,3 therapeutic inertia from polypharmacy fatigue,4 and the cost of novel pharmacotherapies.

It is evident that one important root cause of metabolic disease is the impact of modern diets on our body’s metabolic control systems. Recent observations of durable T2D remission from bariatric surgery provide a better appreciation for the critical role of the gut in nutrient sensing and metabolic control.5,6 We present a theory of a causal mechanism linking nutrient-induced alterations of the gut mucosa to gut neuro-hormonal signaling changes and the metabolic syndrome, which we call the Intestinal Metabolic Balance model. We believe this model provides a useful intellectual framework with which to understand the distinct roles of proximal and distal intestinal segments in metabolic regulation. The model may also aid in the development of novel disease-modifying therapies that can correct the dysregulated metabolic signals from the intestine and stem the tide of metabolic diseases in society.

1Fractyl Health, Inc., Lexington, MA, USA
2Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, California
3Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA

Corresponding Author:
Harith Rajagopalan, M.D., PhD., Fractyl Health, Inc., 17 Hartwell Avenue, Lexington, MA 02421, USA.
Email: harith@fractyl.com
metabolic benefits of certain bariatric surgeries and points to novel disease modifying therapies targeting the gut which have the potential to reduce the metabolic disease burden in society. The model will hopefully prove to be useful in helping to shed light on critical areas where more research is surely needed to better explicate the role of the gut in metabolic dysfunction.

**A New Paradigm Emerges from an Unlikely Origin**

Metabolic surgeries, originally intended for weight loss, have emerged as a treatment approach in T2D with superior metabolic benefits compared to the current standard of care.\(^7,8\) Despite the profound metabolic benefits observed after surgery, little is known about the multiple mechanistic underpinnings leading to these benefits. Interestingly, physiological studies in people undergoing bariatric surgery have surprisingly revealed that many of the metabolic improvements occur before substantial weight loss and these early improvements appear to be independent of the degree of weight loss achieved.\(^9\) In particular, the exclusion of the duodenum from the passage of nutrients by surgical diversion results in weight-independent metabolic improvements associated with a reduction in insulin resistance.\(^10-12\) This effect is notable in its almost immediate onset (within days) and in its reversibility (such as by re-exposure of the duodenum to nutrients). In 2010, Holst and colleagues examined the glucose tolerance of a patient with T2D who underwent a Roux-en-Y gastric bypass surgery (RYGB) and who happened to need a percutaneous G-tube placement directly into the bypassed stomach to enable feeding via the duodenum after the surgery.\(^13\) In this patient, oral delivery of glucose (bypassing the duodenum) led to a markedly superior metabolic profile compared to G-tube delivery of glucose (enabling nutrient transit through the duodenum as if the patient had not had surgery) despite both procedures being performed in this individual *at the same weight and on successive days* (Figure 1). Bypass of the proximal small bowel, and the resulting increased nutrient delivery to the distal intestine, thus appeared to improve glucose homeostasis independently from calorie malabsorption or weight change.\(^14,15\)

These observations have led many to ask if this immediate metabolic benefit is a neurohormonal consequence of preventing duodenal nutrient exposure (the "foregut" theory) or enhancing distal small intestinal nutrient exposure (the

---

**Figure 1. Glucose Metabolism Studies after RYGB.** (a) Diagrammatic representation of RYGB surgery, in which a small gastric pouch is connected surgically to the mid-jejunum, leaving the majority of the stomach, the entire duodenum, and some of the proximal small intestine excluded from the passage of nutrients. Bile acids and pancreatic enzymes continue to pass through the bypassed segment of the small intestine (red dots) while ingested food passes from esophagus through a small gastric pouch and into the connected jejunal portion of the small intestine (blue dots). Reprinted with permission from Blamb/Shutterstock.com. (b) Oral glucose tolerance test with nutrient delivery via the bypassed stomach and duodenum (red circles) versus by the gastric pouch and connected jejunal portion of the small intestine (blue triangles) shows markedly different glucose tolerance curves and higher glucose excursion with duodenal nutrient delivery compared to delivery via the bypass. Reprinted with permission from Dirksen et al.\(^13\)
The Gut as the Body’s Metabolic “Balance”

In addition to its better appreciated role in nutrient absorption, the gastrointestinal tract is the largest endocrine organ in the body and contains an important microbiome and an enteric nervous system. The enteric nervous system includes neural circuits that modulate motor functions, local blood flow, mucosal transport and secretion, and immune and endocrine functions. The lining of the intestine serves as both a food-sensing and hormone-secreting interface for the body. Its mucosal lining is comprised of several cell types, approximately 1% of which are enteroendocrine cells (EECs) that release metabolically active hormones regulated by specific nutrient absorption (or lack thereof) in a finely tuned pattern to help the body maintain adequate fuel supply and metabolic homeostasis in both the fasting and post-prandial states. EECs are also neuroendocrine cells, synaptically communicating with the enteric nervous system via neuropods at their basement membrane and thereby transmitting signals related to nutrient status. Critically, nutrient absorption and nutrient-induced neurohormonal signaling are inextricably linked to one another by the transport of nutrients across the luminal brush border. Because of this, nutrient “sensing,” nutrient absorption, and nutrient-induced neurohormonal impact can be viewed interchangeably. Different EECs along the length of the GI tract secrete different hormones, thus the sensory impact of fuel is regulated not only by the type of nutrients sensed by the mucosa but also the location in the GI tract where those nutrients are sensed.

Why is it that the location of nutrient delivery in the intestine can have such a profound impact on metabolic control? One possibility is that the fundamental abnormality of intestinal metabolic control is one that occurs at the organ level rather than the cellular or molecular level. The intestine in adult mammals is an organ that is known to be able to homeostatically grow or shrink over time to adaptively resize in response to varying environmental conditions (e.g., changes in nutrient delivery). We hypothesize that diets that are high in easily digested fats and sugars represent an important driver of the adaptive resizing of the human intestine, causing mucosal alterations of the small intestine through the stimulus of heightened nutrient delivery. This adaptation leads to hyperplasia of the proximal intestinal mucosa and the simultaneous hypoplasia of the distal intestinal mucosa. In this view, the mucosal adaptation of the proximal intestine to high fat and sugar diets leads to a morphological alteration that correlates with the alterations in neurohormonal signal from the proximal intestine, accelerated nutrient absorption via the proximal intestine, and a reduced basal neurohormonal signal from the distal intestine. The relationship between structural changes of the intestinal mucosa and dysfunctional changes in neurohormonal signaling from the proximal intestine to the rest of the body remains an open question. We believe the net systemic impact of this diet-induced imbalance of proximal/distal
intestinal neurohormonal signals in both the basal and post-prandial states may well be the basis for the dysregulated neurohormonal impact of the gut on the metabolic status in obese and insulin resistant individuals.

Intestinal surgeries that shift the balance of nutrient exposure from the proximal to the distal intestine (including certain bariatric surgeries) achieve weight-independent improvements in metabolic disease control. Moreover, the heightened distal nutrient delivery that invariably occurs as a consequence of duodenal bypass leads to an expansion of the distal intestinal mucosa through a similar process of mucosal adaptation, further amplifying the shift toward more distal hormonal factors after surgical bypass.

Mechanistic studies of duodenal bypass surgery or catheter-based nutrient diversion have highlighted a reduction of adipocyte lipolysis as a potential mediator of this metabolic improvement, perhaps driven by gut-brain signals, gut hormone effects, bile acid signaling, microbiome effects, or combinations of these. This integrated signal is likely achieved via a myriad of effector pathways. It may therefore be better understood by the net effect of cumulative proximal versus distal signals than by the individual effects of any of the signaling molecules therein.

It is remarkable that, despite the amount of evidence supporting the role of the intestine in metabolic control, the precise mechanisms of this control remain elusive. In Figure 2 we show our proposed model of the gut lining as a longitudinal “metabolic balance” for the body and mucosal adaptation as a cellular mechanism within the mucosal lining by which this balance can be altered. Mature individuals who consume a healthy diet have a normal metabolic status with balanced contributions from proximal and distal intestinal neurohormonal signals (Figure 2a) to the body’s basal and post-prandial metabolic state. Individuals who consume diets that are high in fat and sugar (and presumably low in fiber) are predisposed to developing dysfunction of the proximal intestinal mucosa because of the proximal intestine’s adaptation to chronically elevated nutrient exposure. This shifts the metabolic “balance” toward the proximal intestine (with subsequently reduced distal nutrient delivery) and pushes the metabolic state toward hunger, energy utilization, and insulin resistance, all in the setting of excess caloric availability (Figure 2b). Conversely, individuals who undergo duodenal bypass surgery increase distal nutrient delivery, which leads to hypertrophy and hyperplasia of the distal intestinal mucosa. This, in turn, shifts the metabolic balance toward the distal intestine and pushes an individual’s homeostatic status toward satiety, energy storage, and insulin sensitivity and also contributes to weight loss and improved metabolic control. (Figure 2c).

**Evidence for the Metabolic Balance Model**

Experimental data from rats and humans demonstrate that prolonged exposure to a Western diet can lead to an expansion of the duodenal mucosa and an increase in enteroendocrine cell...
GIP excess extend to humans as well. Elevated levels of GIP and similar bariatric surgeries prevent or limit nutrient absorption in the proximal intestine and accelerate delivery of nutrients to the distal intestine, leading to increased distal intestinal neurohormonal signaling. This shifts the gut’s metabolic balance toward satiety and energy storage, contributing to weight loss and improved metabolic control.

It is evident that GIP expression is increased in people with Type 2 Diabetes, non-alcoholic fatty liver disease, and obesity. While the precise molecular consequences of duodenal hyperplasia are not known, increased Gastic Inhibitory Polypeptide (GIP) secretion, increased iron absorption, altered gut-brain signals, bile acid changes, and microbiome alterations have all been invoked as potential mechanisms. GIP is an incretin hormone that contributes to the basal secretion of insulin and glucagon in the fasting state as well as their induced secretion post prandially. It is produced in intestinal cells found predominantly in the proximal small intestine, including the duodenum. In addition to its effects on the alpha cell and beta cell of the pancreas, GIP also has stimulatory effects on the alpha cell and beta cell of the pancreas, GIP has been observed in serum from obese patients and in biopsy samples of duodenal mucosa taken from patients with T2D. It is evident that GIP expression is increased in people with obesity and T2D, but the role of pharmacologic manipulation of the GIP signaling pathway in metabolic control is unclear, with both GIP agonists and antagonists currently in development. In addition, the literature linking GIP to the development of metabolic disease must be interpreted with caution, given that studies have also proposed that GIP may have an insulin-sensitizing effect. Iron absorption occurs primarily in the proximal small intestine, including the duodenum. Also similar to GIP, elevated iron stores are positively associated with insulin resistance, metabolic syndrome, and T2D in humans. The relationship between iron and diabetes is reciprocal: elevated iron stores negatively impact glucose metabolism and glucose metabolism impacts iron pathways in the body. Iron excess predicts the development of T2D while iron depletion appears to protect from metabolic disease. The intestine has also been observed to have alterations in gut-brain, bile acid, and microbiome signaling in animal models and individuals with obesity, as has been reviewed elsewhere.

It is also possible that duodenal hyperplasia does not confer any afferent signal itself but simply acts as a hyperactive accelerator of nutrient uptake and a “gatekeeper” that limits nutrient delivery to the distal gut. When the duodenum of rodents fed a high fat and sugar diet becomes hyperplastic, the distal intestine of the same DIO rodents becomes hypoplastic, which is hypothesized to be due to reduced delivery of nutrients to the distal small intestine. Physiologic characterization of humans and rodent models of T2D and obesity has been associated with decreased GLP-1 and Peptide YY (PYY) secretion that correlate with distal hypoplasia. As with the link between proximal intestinal hyperplasia and GIP excess, strong circumstantial evidence also supports an important hormonal consequence of distal intestinal hypoplasia. As such, the “foregut” mechanism may simply be a mechanism by which duodenal hyperplasia reciprocally diminishes known hindgut effects on satiety and glucose reduction mediated through distal effectors, including GLP-1 and PYY. In summary, while the evidence that duodenal hyperplasia may be pathologically implicated in insulin resistance is quite strong, the afferent mechanistic relationship between duodenal hyperplasia and the metabolic syndrome remains unclear.

The growing body of evidence around gut-segment dependent metabolic effects is not sufficiently explained by existing models of the role of the gut in metabolic control. Our model adds to, but does not replace, our growing understanding of the key integrating roles played by adipose tissue, the brain, and other organs as critical participants in determining metabolic homeostasis. For instance, current theories recognize the role of incretin hormones and the microbiome on insulin kinetics and the role of nutrient signals from the gut in influencing the brain-adipose and brain-liver signaling required for energy mobilization versus energy storage. However, they do not explain the contrasting effects of proximal intestinal and distal intestinal factors on weight, lipolysis, insulin resistance, glycemia,
cardiovascular risk factors. It is possible that the intestinal metabolic imbalance caused by a hyperplastic duodenum drives accelerated fatty acid flux (either through neuronal or hormonal afferent signals), thereby tying the mucosal abnormality to the development of insulin resistance. We believe this gut mucosal metabolic balance model provides a rational explanation for the histological observation of mucosal changes in response to high fat diets along the length of the GI tract, as well as such clinical observations as: (1) the weight-independent benefits of certain duodenum-excluding surgeries, (2) the different responses of nutrient stimulus in the proximal versus distal intestine, (3) the benefits of GLP-1 receptor analogues, and even (4) the benefit of alpha-glucosidase inhibitors (because inhibition of proximal intestinal glucose absorption leads to enhanced distal glucose absorption). Furthermore, the model provides a framework to help interpret the mechanistic basis of the human clinical evidence thus far available and enables the generation of hypotheses that can provide a path forward to new treatments.

There are several unique novel endoscopic interventions under development that have each demonstrated weight independent metabolic benefits. While working via disparate mechanisms, they each harness the potential to reset this putative metabolic imbalance in a minimally invasive and adherence-independent manner by altering the location of intestinal nutrient absorption. Three categories of such promising interventions are worth considering. First, the duodenal-jejunal bypass liner, which is a luminal implant that causes nutrient delivery to bypass the duodenum and proximal jejunum, thereby accelerating nutrient delivery to the distal intestine, has shown promising effects on blood glucose control and weight loss. Second, the jejuno-ileal partial bypass procedure accelerates nutrient delivery to the distal intestine, which has been shown to reduce blood sugar and body weight in individuals with T2D. Third, duodenal mucosal resurfacing (DMR) addresses dysfunctional duodenal neurohormonal signaling via hydrothermal ablation, leading to improved insulin sensitivity and glucose control. Early studies of each of these therapies have also shown decreases in insulin resistance, liver fat content, and body weight, thereby supporting the argument that intestinal interventions show considerable promise in reversing metabolic diseases.

Conclusion

While there are multiple dynamic physiological mechanisms that contribute to the maintenance of metabolic homeostasis, this metabolic balance model of the gut should be viewed as a starting point for further hypothesis generation and testing. What is the link between duodenal dysfunction and insulin resistance? What is the nature of the afferent signal from the gut to the brain, liver, and/or adipose that regulates the balance between lipogenesis and lipolysis and impacts the systemic insulin resistant state? Is there a minimal reducible set of proximal intestinal and/or distal intestinal factors that are sufficient to recapitulate the phenotype of bariatric surgery in a molecular manner (i.e., what are the contributions of gut hormones, bile acids, iron metabolism, neuronal signaling, and the microbiome involved)? We have recently convened a research consortium of scientific and clinical experts to begin delving into these potential questions as a means to better understand the role the gut is playing in metabolic homeostasis.

Though the precise molecular mechanisms may still be unknown, it is possible that entirely new therapeutic approaches can be developed based on this gut metabolic balance model. These approaches may well address the current explosive unmet need for disease modifying therapies by providing non-pharmacological, adherence-independent alternatives to the current standard of care in T2D. Minimally invasive, highly scalable approaches aiming to restore intestinal metabolic equipoise have the potential for far-reaching consequences on human health by tackling one of the upstream, organ-level root causes of the metabolic syndrome rather than simply addressing its narrower downstream consequences, like elevated blood sugar, liver steatosis, or coronary atherosclerosis.

Abbreviations

- Diet-induced obesity (DIO), Enteroendocrine cells (EECs), gastrointestinal (GI), Gastric Inhibitory Polypeptide (GIP), Peptide YY (PYY), Roux-en-Y gastric bypass (RYGB), (T2D) Type 2 Diabetes

Acknowledgments

The authors wish to thank Emily Cozzi, PhD and Kelly White, PhD for their valuable input and assistance in the writing and technical editing of this manuscript.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Harith Rajagopalan and Juan Carlos Lopez-Talavera are full time employees of Fractyl Health, Inc. David Klonoff is a consultant for EoFlow, Fractyl Health, Inc., Lifecare, Novo, Roche Diagnostics, Samsung, and Thirdwayv. Alan Cherrington is a consultant to Fractyl Health, Inc., Abvance, Biocon, Diakard, Metavention, Novo Nordisk, Sekkei Bio, Sensulin Labs, Thetis Pharmaceuticals, vTv Therapeutics. Dr. Cherrington has research contracts with Abvance and Novo Nordisk.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by Fractyl Health, Inc.

ORCID iD

David C. Klonoff https://orcid.org/0000-0001-6394-6862
References

1. Selvin E, Parrinello CM, Daya N, Bergenstal RM. Trends in insulin use and diabetes control in the U.S.: 1988-1994 and 1999-2012. Diabetes Care. 2016;39(3):e33-e35. doi:10.2337/dc15-2229

2. Edelman S, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40(11):1425-1432. doi:10.2337/dc16-1974

3. Edelstein SL. Lack of durable improvements in β-cell function following withdrawald of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care. 2019;42(9):1742-1751. doi:10.2337/dc19-0556

4. Kovacs Burns K, Nicolucci A, Holt RIG, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2®): cross-national benchmarking indicators for family members living with people with diabetes. Diabet Med. 2013;30(7):778-788. doi:10.1111/dme.12239

5. Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the gut in glucose homeostasis. Diabetes Care. 2016;39(6):884-892. doi:10.2337/dc16-0351

6. Duca FA, Waise TMZ, Peppler WT, Lam TKT. The metabolic impact of small intestinal nutrient sensing. Nat Commun. 2021;12(1):903. doi:10.1038/s41467-021-21235-y

7. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. N Engl J Med. 2017;376(7):641-651. doi:10.1056/NEJMoA1600869

8. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964-973. doi:10.1016/S0140-6736(15)00075-6

9. Cummings DE, Overduin J, Shannon MH, Foster-Schubert KE. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat Dis. 2005;1(3):358-368. doi:10.1016/j.soard.2005.03.208

10. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741-749. doi:10.1097/01.sla.0000224726.61448.1b

11. Rubino F, Marescaux J. Effect of duodenal-duodenal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239(1):1-11. doi:10.1097/01.sla.0000102989.54824.fc

12. Wickremesekera K, Miller G, DeSilva Naotunne T, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005;15(4):474-481. doi:10.1381/0960892057323042

13. Dirksen C, Hansen DL, Madshad S, et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care. 2010;33(2):375-377. doi:10.2337/dc09-1374

14. Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22(7):1084-1096. doi:10.1007/s11695-012-0621-4

15. Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011;21(7):896-901. doi:10.1007/s11695-011-0412-3

16. Meister KM, Schauer PR, Brethauer SA, Aminian A. Effect of gastrogastric fistula closure in type 2 diabetes. Obes Surg. 2018;28(4):1086-1090. doi:10.1007/s11695-017-2976-z

17. Jirapinyo P, Thompson AC, Kröner PT, Chan WW, Thompson CC. Metabolic effect of foregut exclusion demonstrated by the impact of gastrogastric fistula on recurrence of diabetes. J Am Coll Surg. 2018;226(3):259-266.e1. doi:10.1016/j.jamcoll.surg.2017.12.015

18. Kamvisi-Lorenz V, Raffaelli M, Bornstein S, Mingrone G. Role of the gut on glucose homeostasis: lesson learned from metabolic surgery. Curr Atheroscler Rep. 2017;19(2):9. doi:10.1007/s11883-017-0642-5

19. Nguyen NQ, Debreceni TL, Bambrick JE, et al. Accelerated intestinal glucose absorption in morbidly obese humans: relationship to glucose transporters, incretin hormones, and glycemia. J Clin Endocrinol Metab. 2015;100(3):968-976. doi:10.1210/jc.2014-3144

20. Salinari S, Carr RD, Guidone C, et al. Nutrient infusion bypassing duodenal-jejunum improves insulin sensitivity in glucose-tolerant and diabetic obese subjects. Am J Physiol Endocrinol Metab. 2013;305(1):E59-E66. doi:10.1152/ajpendo.00559.2012

21. Pfeiffer AFH, Keyhani-Nejad F. High glycemic index metabolic damage – a pivotal role of GIP and GLP-1. Trends Endocrinol Metab. 2018;29(5):289-299. doi:10.1016/j.tem.2018.03.003

22. Angelini G, Castagneto-Gissey L, Casella-Mariolo J, et al. Duodenal-jejunal bypass improves nonalcoholic fatty liver disease independently of weight loss in rodents with diet-induced obesity. Am J Physiol Gastrointest Liver Physiol. 2020;319(4):G502-G511. doi:10.1152/ajpgi.00357.2019

23. Clemmensen C, Müller TD, Woods SC, Berthoud HR, Seeley RJ, Tschöp MH. Gut-brain cross-talk in metabolic control. Cell. 2017;185(5):758-774. doi:10.1016/j.cell.2017.01.025

24. Liddle RA. Neuropods. Cell Mol Gastroenterol Hepatol. 2019;7(4):739-747. doi:10.1016/j.jcmgh.2019.01.006

25. Kuhre RE, Christiansen CB, Saltiel MY, Wewer Albrechtsen NJ, Holst JJ. On the relationship between glucose absorption and glucose-stimulated secretion of GLP-1, neuropeptide, and PYY from different intestinal segments in the rat. Physiol Rep. 2017;5(23):e13507. doi:10.14814/phy2.13507

26. O’Brien LE, Soliman SS, Li X, Bilder D. Altered modes of stem cell division drive adaptive intestinal growth. Cell. 2011;147(3):603-614. doi:10.1016/j.cell.2011.08.048

27. West JA, Tsakmaki A, Huang JHS, et al. Proximal and distal gut mucosa adapt differently to westernized diet, promoting an insulin-resistant dysmetabolic state. Preprint. Posted online January 2019. bioRxiv 822122. doi:10.1101/822122

28. Seeley RJ, Chambers AP, Sandoval DA. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab. 2015;21(3):369-378. doi:10.1016/j.cmet.2015.01.001
29. Grenier-Larouche T, Carreau AM, Geloën A, et al. Fatty acid metabolic remodeling during type 2 diabetes remission after bariatric surgery. *Diabetes*. 2017;66(11):2743-2755. doi:10.2337/db17-0414

30. Thomas C, Giusiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metab*. 2009;10(3):167-177. doi:10.1016/j.cmet.2009.08.001

31. Batterham RL, Cummings DE. Mechanisms of diabetes improvement following bariatric/metabolic surgery. *Diabetes Care*. 2016;39(6):893-901. doi:10.2337/dc16-0145

32. Gmili D, Calcagno A, Dalla Libera L, et al. High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. *Diabetologia*. 2010;53(10):2233-2240. doi:10.1007/s00125-010-1830-9

33. Verdam FJ, Greve JWM, Roosta S, et al. Small intestinal functional GIPR antagonism desensitizes adipocyte GIPR activity mimicking obesity and insulin resistance in diabetic patients. *Diabetes*. 2001;50(11):E379-E383. doi:10.1210/jc.2010-1333

34. Kieffer TJ. Gastro-intestinal hormones GIP and GLP-1. *J Diab Investig*. 2011;6(2):221-227. doi:10.1016/S0012-5459(01)00034-3

35. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. *J Diabetes Investig*. 2010;1(1-2):8-23. doi:10.1111/j.2040-1124.2010.00022.x

36. Bozzini C, Girelli D, Olivieri O, et al. Prevalence of body iron excess in the metabolic syndrome. *Diabetes Care*. 2005;28(8):2061-2063. doi:10.2337/diabcare.28.8.2061

37. Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. *Am J Physiol Endocrinol Metab*. 2006;290(3):E550-E559. doi:10.1152/ajpendo.00326.2004

38. Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide functionally reconstitutes beta-cell function and insulin sensitivity in type 2 diabetes. *J Clin Endocrinol Metab*. 2021;106(2):388-396. doi:10.1210/clinem/dgaa863

39. Killion EA, Chen M, Falsey JR, et al. Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. *Nat Commun*. 2020;11(1):4981. doi:10.1038/s41467-020-18751-8

40. Killion EA, Wang J, Yie J, et al. Anti-obesity effects of GIPR agonists alone and in combination with GLP-1R agonists in preclinical models. *Sci Transl Med*. 2018;10(472):eaat3392. doi:10.1126/scitranslmed.aat3392

41. Samms RJ, Christe ME, Collins KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. *J Clin Invest*. 2021;131(12):e146353. doi:10.1172/jci146353

42. Fernández-Real JM, López-Berméjo A, Ricart W. Cross-talk between iron metabolism and diabetes. *Diabetes*. 2002;51(8):2348-2354. doi:10.2337/diabetes.51.8.2348

43. Legakis IN, Tzioras C, Phenekos C. Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. *Diabetes Care*. 2003;26(1):252. doi:10.2337/diabetes.26.1.252

44. le Roux CW, Batterham RL, Aylwin SJB, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. *Endocrinology*. 2006;147(1):3-8. doi:10.1210/en.2005-0972

45. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. *J Clin Endocrinol Metab*. 2001;86(8):3717-3723. doi:10.1210/jcem.86.8.7750

46. Yi CX, Tschöp MH. Brain-gut-adipose tissue communication pathways at a glance. *Dis Model Mech*. 2012;5(5):583-587. doi:10.1242/dmm.009902

47. Schertzer JD, Lam TKT. Peripheral and central regulation of insulin by the intestine and microbiome. *Am J Physiol Endocrinol Metab*. 2021;320(2):E234-E239. doi:10.1152/ajpendo.00547.2020

48. Jujić A, Nilsson PM, Atabaki-Pasdar N, et al. Glucose-dependent insulinotropic peptide in the high-normal range is associated with increased carotid intima-media thickness. *Diabetes Care*. 2021;44(1):224-230. doi:10.2337/dc20-1318

49. van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. *Gut*. 2020;69(2):295-303. doi:10.1136/gutjnl-2019-323608

50. Mingrone G, van Baar ACG, Devière J, et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. *Gut*. Published online February 17, 2021. doi:10.1136/gutjnl-2020-323608

51. Ryu M, Agoston AT, Thompson CC. Endoscopic intestinal bypass creation by using self-assembling magnets in a porcine model. *Gastrointest Endosc*. 2016;83(4):821-825. doi:10.1016/j.gie.2015.10.023

52. Fried M, Dolezalova K, Chambers AP, et al. A novel approach to glycemic control in type 2 diabetes mellitus, partial jejunal diversion: pre-clinical to clinical pathway. *BMJ Open Diabetes Res Care*. 2017;5(1):1-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706485/pdf/bmjdrcc-2017-000431.pdf